Summit Therapeutics (SMMT) Gross Margin (2017 - 2020)

Summit Therapeutics (SMMT) has 4 years of Gross Margin data on file, last reported at 2345.34% in Q1 2020.

• Quarterly Gross Margin fell 71574.0% year-over-year to 2345.34% in Q1 2020, while the trailing twelve-month figure through Mar 2020 was 128.56% (up 12280.0% YoY) and the FY2019 annual result came in at 4383.58%, changed N/A from the prior year.
• Gross Margin declined to 2345.34% in Q1 2020, from 80.82% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 80.82% in Q4 2019 to a low of 6205.65% in Q4 2019.
• A 4-year average of 1452.01% and a median of 328.43% in 2017 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2018 — Gross Margin jumped 16215 bps — and 2019, when it plunged 495261 bps.
• Tracing SMMT's Gross Margin over 4 years: stood at 197.34% in 2017, then sank by 602 bps to 1385.04% in 2018, then soared by 106 bps to 80.82% in 2019, then sank by 3002 bps to 2345.34% in 2020.
• The last three Gross Margin figures came in at 2345.34% (Q1 2020), 80.82% (Q4 2019), and 6205.65% (Q4 2019), per Business Quant data.